Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Fifth Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 8 current clinical trials in our China register. 5 are recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Capecitabine, Cisplatin and Gemcitabine. The most-studied condition is Head and Neck Squamous Cell Carcinoma.

ClinicalTrials.gov trials by status

Recruiting563%
Not yet open113%
Active, closed225%

Trials by phase

Phase 2338%
Not applicable225%
Phase 1225%
Observational113%

Clinical trials sponsored by Fifth Affiliated Hospital, Sun Yat-Sen University

8 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
The Efficacy and Safety of Low-dose Radiotherapy Combined With Sintilimab and Temozolomide in Recurrent Glioblastoma NCT06220552 · ClinicalTrials.gov ↗ · Recurrent Glioblastoma Drug: Sintilimab	Phase 2	Recruiting	2023-12	China
Study on the Quantitative Assessment of the Risk of Hepatocellular Carcinoma in Patients With Chronic Liver Disease Using Multi-parameter Magnetic Resonance Imaging NCT06060769 · ClinicalTrials.gov ↗ · Cirrhosis； Tumor	Observational	Recruiting	2023-09	China
Radiotherapy Combined With PD-1 Monoclonal Antibody and Capecitabine in the Treatment of Nasopharyngeal Carcinoma NCT05290194 · ClinicalTrials.gov ↗ · Radiotherapy, PD-1 Inhibitor, Capecitabine Drug: Capecitabine	Phase 2	Recruiting	2022-03	China
The Efficacy and Safety of De-escalated Postoperative Radiotherapy in Locally Advanced HNSCC With pCR/MPR NCT05854823 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma	Not applicable	Recruiting	2023-04	China
Thiotepa, Cyclophosphamide, Clarithromycin and Cytarabine NCT06060782 · ClinicalTrials.gov ↗ · Burkitt Lymphoma, Lymphoblastic Lymphoma, Adult, Acute Lymphoblastic Leukemia, Adult	Phase 1	Recruiting	2024-03	China
Clinical Study on the Efficacy of Single-port Inflatable Mediastinoscopy Combined With Laparoscopic-assisted Small Incision Surgery and Thoracoscopy Combined With Laparoscopic Surgery for Radical Esophagectomy NCT05105945 · ClinicalTrials.gov ↗ · Esophageal Cancer	Not applicable	Not yet open	2021-11	China
The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC NCT05343325 · ClinicalTrials.gov ↗ · Head and Neck Squamous Cell Carcinoma, Neoadjuvant Treatment Drug: Tislelizumab	Phase 2	Active, closed	2022-03	China
Toripalimab Combined With Gemcitabine and Cisplatin Treating Resectable Locally Advanced HNSCC NCT04947241 · ClinicalTrials.gov ↗ · Locally Advanced Head and Neck Squamous Cell Carcinoma, Neoadjuvant Therapy Drugs: Cisplatin, Gemcitabine	Phase 1	Active, closed	2020-12	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Fifth Affiliated Hospital, Sun Yat-Sen University trials

5 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Capecitabine1 Cisplatin1 Gemcitabine1 Sintilimab1 Tislelizumab1

Conditions in Fifth Affiliated Hospital, Sun Yat-Sen University trials

14 conditions

Head and Neck Squamous Cell Carcinoma2 Recurrent Glioblastoma1Cirrhosis； Tumor1Radiotherapy1 PD-1 Inhibitor1Capecitabine1Nasopharyngeal Carcinoma1Neoadjuvant Treatment1Locally Advanced Head and Neck Squamous Cell Carcinoma1 Neoadjuvant Therapy1Burkitt Lymphoma1Lymphoblastic Lymphoma, Adult1Acute Lymphoblastic Leukemia, Adult1Esophageal Cancer1

By trial register

Register	Trials	Recruiting
Clinical trials in China	8	5

A trial with sites in more than one country appears in each of those registers.

Other sponsors in Head and Neck Squamous Cell Carcinoma

Sponsor	Trials
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University	7
West China Hospital	6
Merus	3
Beijing Tongren Hospital	3
ALX Oncology	2
Bicara Therapeutics	1
Rajiv Gandhi Cancer Institute & Research Center, India	1
CSPC Megalith Biopharmaceutical	1
Man Hu	1

Sponsors with the most current trials registered for this condition.

Questions about Fifth Affiliated Hospital, Sun Yat-Sen University trials

How many clinical trials does Fifth Affiliated Hospital, Sun Yat-Sen University sponsor?

Fifth Affiliated Hospital, Sun Yat-Sen University is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Fifth Affiliated Hospital, Sun Yat-Sen University trials recruiting?

Yes. 5 of its 8 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Fifth Affiliated Hospital, Sun Yat-Sen University testing?

Its current trials name 5 drugs and biologicals as interventions. The most frequent are Capecitabine (1), Cisplatin (1), Gemcitabine (1), Sintilimab (1) and Tislelizumab (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Fifth Affiliated Hospital, Sun Yat-Sen University clinical trials